Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy.
An analysis of clinical records after the introduction of highly active antiretroviral therapy (HAART) in Mexico showed a lower prevalence and severity of immune recovery uveitis when HIV-infected patients started HAART after completing cytomegalovirus retinitis treatment than when treatments were concomitant. The findings suggest a protective role of delaying HAART until cytomegalovirus retinitis is controlled.
Ortega-Larrocea
Gabriela
G
Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional Enfermedades Respiratorias, Mexico City, México.
Espinosa
Enrique
E
Reyes-Terán
Gustavo
G
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D000328:Adult; D018791:CD4 Lymphocyte Count; D003587:Cytomegalovirus; D017726:Cytomegalovirus Retinitis / Q000150:complications* / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D015497:HIV-1; D006801:Humans; D015994:Incidence; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology